Prognostic value of urinary protein in primary systemic amyloidosis (AL)

Morie Gertz, R. A. Kyle

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

In 153 patients with biopsy-proven primary systemic amyloidosis (AL), serum creatine level correlated with median survival (creatinine ≤ 115 μmol/L [1.3 mg/dL], 25.6 months; creatinine > 115 μmol/L [1.3 mg/dL], 14.9 months; P = 0.007). The 24-hour urine total protein excretion was not correlated with survival. Patients who excreted monoclonal lambda light chains in the urine had an inferior survival (12 months) compared with those with kappa (30 months) or no monoclonal protein (35 months) in the urine (P = 0.01). The presence of lambda monoclonal protein was not associated with a higher median creatinine level. A monoclonal protein was detected in the urine in 76% of patients; when patients with more than 1 g of protein in the urine were studied, however, a monoclonal protein was detectable in 86%. The overall kappa-lambda ratio was 1:2.56, but as the urinary protein loss increased, the kappa-lambda ratio shifted to 1:4.7 for those with more than 3 g of protein in the urine.

Original languageEnglish (US)
Pages (from-to)313-317
Number of pages5
JournalAmerican Journal of Clinical Pathology
Volume94
Issue number3
StatePublished - Jan 1 1990

Fingerprint

Urine
Proteins
Creatinine
Survival
Primary amyloidosis
Creatine
Biopsy
Light
Serum

Keywords

  • amyloidosis
  • creatinine
  • monoclonal light chain
  • nephrotic syndrome
  • survival

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Prognostic value of urinary protein in primary systemic amyloidosis (AL). / Gertz, Morie; Kyle, R. A.

In: American Journal of Clinical Pathology, Vol. 94, No. 3, 01.01.1990, p. 313-317.

Research output: Contribution to journalArticle

@article{e6afcfa97f0244cf820495c7b10ae07b,
title = "Prognostic value of urinary protein in primary systemic amyloidosis (AL)",
abstract = "In 153 patients with biopsy-proven primary systemic amyloidosis (AL), serum creatine level correlated with median survival (creatinine ≤ 115 μmol/L [1.3 mg/dL], 25.6 months; creatinine > 115 μmol/L [1.3 mg/dL], 14.9 months; P = 0.007). The 24-hour urine total protein excretion was not correlated with survival. Patients who excreted monoclonal lambda light chains in the urine had an inferior survival (12 months) compared with those with kappa (30 months) or no monoclonal protein (35 months) in the urine (P = 0.01). The presence of lambda monoclonal protein was not associated with a higher median creatinine level. A monoclonal protein was detected in the urine in 76{\%} of patients; when patients with more than 1 g of protein in the urine were studied, however, a monoclonal protein was detectable in 86{\%}. The overall kappa-lambda ratio was 1:2.56, but as the urinary protein loss increased, the kappa-lambda ratio shifted to 1:4.7 for those with more than 3 g of protein in the urine.",
keywords = "amyloidosis, creatinine, monoclonal light chain, nephrotic syndrome, survival",
author = "Morie Gertz and Kyle, {R. A.}",
year = "1990",
month = "1",
day = "1",
language = "English (US)",
volume = "94",
pages = "313--317",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Prognostic value of urinary protein in primary systemic amyloidosis (AL)

AU - Gertz, Morie

AU - Kyle, R. A.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - In 153 patients with biopsy-proven primary systemic amyloidosis (AL), serum creatine level correlated with median survival (creatinine ≤ 115 μmol/L [1.3 mg/dL], 25.6 months; creatinine > 115 μmol/L [1.3 mg/dL], 14.9 months; P = 0.007). The 24-hour urine total protein excretion was not correlated with survival. Patients who excreted monoclonal lambda light chains in the urine had an inferior survival (12 months) compared with those with kappa (30 months) or no monoclonal protein (35 months) in the urine (P = 0.01). The presence of lambda monoclonal protein was not associated with a higher median creatinine level. A monoclonal protein was detected in the urine in 76% of patients; when patients with more than 1 g of protein in the urine were studied, however, a monoclonal protein was detectable in 86%. The overall kappa-lambda ratio was 1:2.56, but as the urinary protein loss increased, the kappa-lambda ratio shifted to 1:4.7 for those with more than 3 g of protein in the urine.

AB - In 153 patients with biopsy-proven primary systemic amyloidosis (AL), serum creatine level correlated with median survival (creatinine ≤ 115 μmol/L [1.3 mg/dL], 25.6 months; creatinine > 115 μmol/L [1.3 mg/dL], 14.9 months; P = 0.007). The 24-hour urine total protein excretion was not correlated with survival. Patients who excreted monoclonal lambda light chains in the urine had an inferior survival (12 months) compared with those with kappa (30 months) or no monoclonal protein (35 months) in the urine (P = 0.01). The presence of lambda monoclonal protein was not associated with a higher median creatinine level. A monoclonal protein was detected in the urine in 76% of patients; when patients with more than 1 g of protein in the urine were studied, however, a monoclonal protein was detectable in 86%. The overall kappa-lambda ratio was 1:2.56, but as the urinary protein loss increased, the kappa-lambda ratio shifted to 1:4.7 for those with more than 3 g of protein in the urine.

KW - amyloidosis

KW - creatinine

KW - monoclonal light chain

KW - nephrotic syndrome

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=0025087767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025087767&partnerID=8YFLogxK

M3 - Article

C2 - 2118721

AN - SCOPUS:0025087767

VL - 94

SP - 313

EP - 317

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -